<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03333928</url>
  </required_header>
  <id_info>
    <org_study_id>HTD1801.PCT003</org_study_id>
    <nct_id>NCT03333928</nct_id>
  </id_info>
  <brief_title>A POC and Dose-Ranging Study of HTD1801 in PSC Patients</brief_title>
  <official_title>A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adult Subjects With Primary Sclerosing Cholangitis (PSC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighTide Biopharma Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighTide Biopharma Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates HTD1801 in the treatment of Primary Sclerosing Cholangitis (PSC) in
      adults. The subjects will be randomised to 3 treatment groups, to receive 500mg, 1000mg and
      placebo, bid.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 9, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A primary parallel group comparison for a 6-week treatment, followed by a 6-week dose-controlled extension, and followed by a 6-week random withdrawal.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of alkaline phosphatase (ALP)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of alkaline phosphatase (ALP)</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and severity of adverse events</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>frequency and severity of adverse events</measure>
    <time_frame>up to 18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Primary Sclerosing Cholangitis (PSC)</condition>
  <arm_group>
    <arm_group_label>500mg HTD1801, bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>1000mg HTD1801, bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo, bid</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HTD1801</intervention_name>
    <description>HTD1801 tablets, 250mg</description>
    <arm_group_label>500mg HTD1801, bid</arm_group_label>
    <arm_group_label>1000mg HTD1801, bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>tablets manufactured to mimic HTD1801 tablets</description>
    <arm_group_label>placebo, bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female between 18 and 75 years of age;

          -  Have a clinical diagnosis of PSC as evident by chronic cholestasis of more than six
             months duration with either a consistent magnetic resonance cholangiopancreatography
             (MRCP)/endoscopic retrograde cholangiopancreatography (ERCP) showing sclerosing
             cholangitis;

          -  If subjects have Inflammatory Bowel Disease (IBD) they will be eligible to
             participate. If a subject has IBD, documented evidence of IBD must have been evident
             by prior endoscopy or in previous medical records for ≥6 months. In addition, subjects
             may only enter the study with a Partial Mayo Score of 0-4, inclusively. Subjects who
             are on treatment are allowed, provided they are stable for 3 months if taking:

               1. 5-amino salicylic acid drugs,

               2. azathioprine,

               3. 6-mercaptopurine, or methotrexate

               4. biologics;

          -  Have a serum ALP ≥1.5 × upper limit of normal (ULN);

          -  Be able to understand and sign a written informed consent form (ICF);

          -  Subjects receiving allowed concomitant medications need to be on stable therapy for 28
             days prior to the Baseline Visit.

        Exclusion Criteria:

          -  Presence of documented secondary sclerosing cholangitis (such as ischemic cholangitis,
             recurrent pancreatitis, intraductal stone disease, severe bacterial cholangitis,
             surgical or blunt abdominal trauma, recurrent pyogenic cholangitis,
             choledocholithiasis, toxic sclerosing cholangitis due to chemical agents, or any other
             cause of secondary sclerosing cholangitis) on prior clinical investigations;

          -  Small duct PSC;

          -  Presence of percutaneous drain or bile duct stent;

          -  History of cholangiocarcinoma or high clinical suspicion of dominant stricture within
             1 year by MRCP/ERCP or clinical judgement;

          -  Ascending cholangitis within 60 days prior to Screening;

          -  Alcohol consumption greater than 21 units/week for males or 14 units/week for females
             (one unit of alcohol is ½ pint of beer [285 mL], 1 glass of spirits [25 mL] or 1 glass
             of wine [125 mL]);

          -  Prior or planned liver transplantation;

          -  Presence of alternative causes of chronic liver disease, including alcoholic liver
             disease, nonalcoholic steatohepatitis, primary biliary cirrhosis, autoimmune
             hepatitis;

          -  Platelet count below 125,000/mm3, albumin below 3.0 g/dL, International Normalized
             Ratio (INR) &gt; 1.2, or a history of ascites, or encephalopathy, or history of
             esophageal variceal bleeding;

          -  Severe active IBD or flare in colitis activity within the last 90 days requiring
             intensification of therapy beyond baseline treatment;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Susan M. Gamble, Ph. D.</last_name>
    <phone>+1 301-801-8815</phone>
    <email>clinical.trials@hightidebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Colorado, Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jada Boyd</last_name>
      <phone>303-724-1866</phone>
      <email>jada.boyd@ucdenver.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lisa Forman, MD</last_name>
      <phone>720-848-2292</phone>
      <email>lisa.forman@ucdenver.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Lisa Forman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Levy, MD</last_name>
      <phone>305-243-4615</phone>
      <email>clevy@med.miami.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tiffannia T Grant</last_name>
      <phone>305-243-4649</phone>
      <email>t.grant11@med.miami.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Levy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Beatty, RN</last_name>
      <phone>502-852-3383</phone>
      <email>Karen.beatty@louisville.edu</email>
    </contact>
    <contact_backup>
      <last_name>Matthew Cave, MD</last_name>
      <phone>502-852-6189</phone>
      <email>matt.cave@louisville.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Matthew C. Cave, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Medical Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brook A Quist, CRC</last_name>
      <phone>206-386-2427</phone>
      <email>Brook.quist@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Jodie Davila, RN</last_name>
      <phone>206-215-4384</phone>
      <email>Jodie.davila@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Kris V. Kowdley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Gemmell, MBA, CRC</last_name>
      <phone>206-744-7063</phone>
      <email>lgemmell@medicine.washington.edu</email>
    </contact>
    <contact_backup>
      <last_name>Peter Nguyen</last_name>
      <phone>206-744-3402</phone>
      <email>hnguyen@medicine.washington.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Landis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>November 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2017</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

